Table 1 Distribution of matching criteria and other patient characteristics in the cohort of patients receiving 5 × 5 Gy (n = 32) and in those patients receiving 10 × 3 Gy (n = 64)
5 × 5 Gy N patients | 10 × 3 Gy N patients | P | |
|---|---|---|---|
Type of primary tumor | 1.00 | ||
Breast cancer | 7 (22%) | 14 (22%) | |
Prostate cancer | 2 (6%) | 4 (6%) | |
Myeloma/lymphoma | 3 (9%) | 6 (9%) | |
Lung cancer | 9 (28%) | 18 (28%) | |
Other tumors | 11 (34%) | 22 (34%) | |
Ambulatory prior to radiotherapy | 1.00 | ||
Not ambulatory | 12 (38%) | 24 (38%) | |
Ambulatory | 20 (63%) | 40 (63%) | |
Time developing motor deficits prior to radiotherapy | 1.00 | ||
Faster development (1–7 days) | 9 (28%) | 18 (28%) | |
Slower development (> 7 days) | 23 (72%) | 46 (72%) | |
Interval between tumor diagnosis and MSCC | 1.00 | ||
≤ 12 months | 17 (53%) | 34 (53%) | |
> 12 months | 15 (47%) | 39 (47%) | |
Visceral metastases at the time of radiotherapy | 1.00 | ||
No | 11 (34%) | 22 (34%) | |
Yes | 21 (66%) | 42 (66%) | |
Median age (range) | 63 (36–79) years | 65 (38–86) years | 0.35 |
Gender | 0.83 | ||
Female | 13 (41%) | 28 (44%) | |
Male | 19 (59%) | 36 (56%) | |
Eastern Cooperative Oncology Group performance score | 0.66 | ||
1–2 | 15 (47%) | 26 (41%) | |
3–4 | 17 (53%) | 38 (59%) | |
Number of vertebrae affected by MESCC | 0.83 | ||
1–2 | 20 (63%) | 38 (59%) | |
3 | 12 (38%) | 26 (41%) | |
Other bone metastases at the time of radiotherapy | 1.00 | ||
No | 7 (22%) | 15 (23%) | |
Yes | 25 (78%) | 49 (77%) |